Phasic dysfunction of dopamine transmission in Tourette's syndrome evaluated with 99mTc TRODAT-1 imaging

Psychiatry Res. 2007 Oct 15;156(1):75-82. doi: 10.1016/j.pscychresns.2007.01.003. Epub 2007 Aug 22.

Abstract

This study investigated the complex dysregulation of the dopaminergic neurotransmitter system in Tourette's syndrome (TS) patients challenged with methylphenidate (MPH). Eight drug-naïve male patients (aged 21-25 years) who met DSM-IV criteria for TS and had a mean disease severity of 25 on the Yale Global Tic Severity Scale were recruited. Brain (99m)TC TRODAT-1 dopamine transporter (DAT) single photon emission computed tomography (SPECT) was performed 5 days before, and 2 h after 10 mg of orally administered MPH. Eight age-matched healthy males served as controls. Repeated measures analysis of variance was used to measure differences in DAT-binding ratios before and after MPH challenge between the TS patients and controls. The DAT-binding ratios decreased significantly after MPH treatment in both groups. However, a significant interaction between group and MPH effects was found only in the right caudate, which was mainly due to a smaller decline of the DAT-binding ratio after MPH in the TS group than in the controls. Such a distinction was not found in the other striatal sub-regions in the two groups. No correlation, however, was observed between the tic severity score and DAT-binding ratio measured from the whole striatum or its sub-regions. The observed change in the DAT-binding ratio might indicate a functional abnormality of the dopaminergic system in the right caudate nucleus of TS patients. Future studies exploring dopamine transmission are thus needed to understand the pathophysiology of TS.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Brain / diagnostic imaging
  • Brain / metabolism
  • Caudate Nucleus / diagnostic imaging
  • Caudate Nucleus / metabolism
  • Central Nervous System Stimulants / therapeutic use
  • Dopamine / metabolism*
  • Humans
  • Male
  • Methylphenidate / therapeutic use
  • Organotechnetium Compounds*
  • Putamen / diagnostic imaging
  • Putamen / metabolism
  • Radiopharmaceuticals*
  • Tomography, Emission-Computed, Single-Photon
  • Tourette Syndrome* / diagnosis
  • Tourette Syndrome* / drug therapy
  • Tourette Syndrome* / metabolism
  • Tropanes*

Substances

  • Central Nervous System Stimulants
  • Organotechnetium Compounds
  • Radiopharmaceuticals
  • Tropanes
  • technetium Tc 99m TRODAT-1
  • Methylphenidate
  • Dopamine